



Introduction of



May. 2021.



CONTENTS

- 1 Company Highlights**
- 2 Vision & Core Value**
- 3 History**
- 4 Organization**
- 5 Business Portfolio**



1 Company Highlights

Business

- Dermal Fillers (Classified as Medical Device VI)
- Research and Development of New Medical Devices and Formulations
- Cosmetics, Health Functional Foods and Quasi-Drugs
- OEM (Original Equipment Manufacturing)

Manufacturing Facility

- Prefilled Syringes (Used Fully Automatic Filling Machine)
- ISO 13485:2016 Certificated (Medical Device Management System)
- GMP Certificated for Medical Devices class VI (Ongoing)

Key Numbers (as of 2021)



2 Vision & Core Value

Our Philosophy

“Linking the beauties of the world & Sharing the benefits for your satisfying life”

Our Vision

Constantly link the beauties of the world everywhere

Core Value



Basic

Practice the basic principles in all situations – Quality, Compliance, Safety

Respect

Create synergy with respecting each other’s differences and forming a trust relationships

Together

Realize sustainable win-win with partners and end users based on trust

Globalization

Create new demands and needs of the world through creative thinking and enthusiasm


3 History

We entered the beauty industry as a small medical device distributor.

We have been able to analyze the global beauty related demands and understand the market. Based on this, it was possible to develop into a more competent trading company based in South Korea through appropriate supply.

We have been constantly discovering products that can provide high satisfaction and safety at a more reasonable price. And struggling to meet the higher demands for beauty. As a result, we built a factory that manufactures and produces cosmetic filler-PUFiLLIS®.

We have exclusive import and handling, intermediary trade, and import and export experience for the past 6 years, and added manufacturing technology, know-how, and facilities for medical devices. We are ready for a fresh start with you.



4 Organization

CEO Chief Executive Officer

CTO Chief Technology Officer

COO Chief Operating Officer

Advisory Group Related industry experts, doctors, and professors in South Korea

R&D Lab

Research & Development Laboratory

- Product safety improvement
- Establishment of QC guidelines
- Next product development & Line-up expansion

Production Division

- Product manufacturing
- RA(Regulatory Affairs)
- QA(Quality Assurance) / QC (Quality Control)

Sales Division

- Business strategy planning and marketing
- Search for global & domestic partnerships
- Supplying the products to partners (Including overseas)

Management Division

- Management support of all parts
- Planning & evaluation of Business Strategy
- Reinforcement the value of brand & company

5 Business Portfolio

Our business portfolio consists of 3 main components

Manufacturing

- Highly Regulated GMP Level
- Single product Line to eliminates the risk of cross-contamination
- Advanced Facility with Stable Capacity & Quality Control
- OEM




Marketing & Sales

- Successful Overseas Market Development
- Handling Medical Devices, Cosmetics, Health Functional Foods, and Quasi-Drugs



R&D

- Raw material development as a cosmetic filler and compound for cartilage regeneration
- Drug Delivery agents (DDa)



5.1 Manufacturing

Highly Regulated GMP Level

ISO 13485:2016 and Korean GMP(in progress) recognized in terms of strict safety regulations.

- Required Validations (PV, MV, CV, CSV, Sterilization, Shipping)
- Constant Post Marketing Surveillance to Ensure Product Safety

MI-LINKER has passed all the required ISO13485:2016 to manufacture the filler (injection; medical device – class III)

And Korean GMP is in progress with the goal of approval in the second half of 2021.

- Guaranteed Safety
- High Quality



5.1 Manufacturing

New Generation Polymer Filler

This is absorbent mid-term filler that maintains optimal viscoelasticity and increases safety by **extremely removing harmful unreacted monomers (<0.1ppm)** that inevitable occur during manufacturing.

- Hydrophilic Hydrogel
- 3.75% Polyacrylamide & 96.25% Sodium Chloride Solution
- Slowly absorbed by macrophages and excreted in urine
- Light material as like pure water
- 3D Matrix Structure
- Line-up: 1ml, 10ml



Safety

- Residual Monomer ≈ 0
- In vitro excretion
- Hydrophilic



Efficacy

- Stable Viscoelasticity
- Biocompatibility
- Long-duration




Expandability

- Various Indications (Face, Body)
- Synthetic ease with other substances
- High potential as a DDa

5.1 Manufacturing

Certifications

- ISO13485:2016 Certified for Medical Device
- Certificate of Free Sales by KFDA
- Patent Registration
- Product/Completed Operations Liability (\$100,000)
- Philippines FDA (CPR ongoing)



5.2 Marketing & Sales

Products handled

Medical Device

PUFILLIS®

- Polymer Filler (Graft/Prosthesis)
- KFDA FSC (class VI)
- Made in Korea



AQUAFILLING® (Interruption)

- Polymer Filler (Graft/Prosthesis)
- CE, KFDA
- Made in Czech Rep.



Cosmetics

MI ARCA®

- PDRN + Growth Factor
- Ampoule Type (for MTS)



HAEMRILLA®

- Functional Natural Cosmetics
- ECO Cert
- All-in-One concept



Heath Functional Foods

WEKIDS LACTO-I®

- Probiotics Powder (for Kids)
- Patented DANISCO material



LACTO-I® Probiotics

- Probiotics Tablet (for Adult)
- 10 billion Lactobacillus + Mesima



Quasi-Drugs


AirQueen® Nano Mask

- FDA, CE FFP2



5.2 Marketing & Sales

Global Activity



5.3 R&D

Our R&D consists of Government Sponsored Research and Co-partnership with University.

As a result, we have successfully obtained meaningful outputs such as patent, and new insights from the research conducted during product development.

Recently, we are going to proceed on an interesting topic based on our patents. In addition, our technology will continue to develop not only for cosmetic purposes, but also for potential as a therapeutic agent.

Completed Research

Organization	Research Topic
Ewha Womans University College of Pharmacy	Study on the physical properties of PAAG according to the polymerization ratio
	Methodology for removing PAAG residual monomer
Hanyang University Bio-function materials & tissue engineering lab	Analysis of results for polymeric monomers
	Cytotoxicity test according to polymerization ratio
Hoseo Analytical Research Institute of Medical Science & Medvill co., Ltd.	Verification of PAAG's excretion mechanism through animal testing

Research to Proceed

Organization	Research Topic
-	Develop of Biocompatible materials that Synthesized PAAG and other raw substances (Hyaluronic Acid, Collagen)
	Research on next generation injections for Cartilage Treatment
Hanyang University Bio-function materials & tissue engineering lab	Comparison of Physical properties between Polymer Products & Verification of Biocompatibility
Ewha Womans University College of Pharmacy	Study on Possibility of PAAG as a Drug Delivery Agent

CONTACT

- **Tel.** +82 2 6959 5605
- **Fax** +82 2 6959 5606
- **E-Mail** info@mi-linker.com
- **HQ & Factory** 302, Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, 13201 Rep of Korea
- **Website** www.mi-linker.com

